Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16.
Aimmune Therapeutics plans to list on the Nasdaq under the symbol AIMT. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as lead managers on the deal.
